Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Income from Continuing Operations: 2020-2023

Historic Income from Continuing Operations for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$54.8 million.

  • Immuneering's Income from Continuing Operations fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • Immuneering's Income from Continuing Operations amounted to -$54.8 million in FY2023, which was down 8.50% from -$50.5 million recorded in FY2022.
  • Immuneering's Income from Continuing Operations' 5-year high stood at -$17.0 million during FY2020, with a 5-year trough of -$54.8 million in FY2023.
  • In the last 3 years, Immuneering's Income from Continuing Operations had a median value of -$50.5 million in 2022 and averaged -$46.3 million.
  • Data for Immuneering's Income from Continuing Operations shows a maximum YoY crashed of 96.81% (in 2021) over the last 5 years.
  • Immuneering's Income from Continuing Operations (Yearly) stood at -$17.0 million in 2020, then tumbled by 96.81% to -$33.5 million in 2021, then tumbled by 50.63% to -$50.5 million in 2022, then declined by 8.50% to -$54.8 million in 2023.